Loading...
•
Dec 31, 2020
Trevena Q4 2020 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of its 2020 and 2021 year-to-date operational highlights.
Key Takeaways
Trevena, Inc. reported a net loss attributable to common stockholders of $11.9 million, or $0.08 per share, for the fourth quarter of 2020. Year-end cash and cash equivalents were $109.4 million as of December 31, 2020, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements through the fourth quarter of 2022.
OLINVYK™ approved in U.S.; customer-facing teams now fully deployed
Primary study completion for TRV027 in COVID-19 patients expected in 1H 2021
IND for TRV045 (S1P1 receptor modulator) on track for 1H 2021; focus in epilepsy and neuropathic pain
Year-end cash of $109.4M funds operations through YE 2022
Revenue by Segment
Forward Guidance
The Company believes that cash and cash equivalents of $109.4 million as of December 31, 2020, will be sufficient to fund the Company’s operating expenses and capital expenditure requirements through the fourth quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...